Jul 14, 2026Study finds frailty risks with GLP-1 drugs in older adultsA large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.Jul 14, 2026·1 source00
May 28, 2026CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug PlansCVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.May 28, 2026·2 sources00
May 3, 2026Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.May 3, 2026·1 source00
